The extent of coronary stenosis and the level of antibodies to atherogenic lipoproteins in patients with coronary heart disease

  • Authors: Urazgil'deeva S.A.1, Titkov A.Y.1, Vasina L.V.1, Tsaregorodtseva V.V.1, Gurevich V.S.1, Urazgildeeva SA2, Titkov AY.3, Vasina LV3, Tsaregorodtseva VV2, Gurevich VS2
  • Affiliations:
    1. I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg
    2. L.G. Sokolov city hospital № 122, St-Petersburg
  • Issue: Vol 83, No 9 (2011)
  • Pages: 10-13
  • Section: Editorial
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/30887
  • Cite item

Abstract


Aim. To study association between the level of antibodies to oxidized low-density lipoproteins (anti-OLDL) and the extent of coronary stenosis (CS) in patients with coronary heart disease (CHD).
Material and methods. Sixty CHD patients were examined for titer of anti-OLDL, levels of total cholesterol (TC), LDLP cholesterol, HDLP cholesterol, triglycerides. Selective coronarography (SC) was made on demand.
Results. Elevated titer of anti-OLDL was found only in 12 examinees. It was significantly lower in CHD women than in men. No significant differences by anti-OLDL were found in CHD patients with and without significant risk factors. SC registered in all CHD examinees local stenosis of different severity. Stenosis in 3 coronary arteries was detected in 31 cases, in 2 coronary arteries - in 14, in 1 coronary artery - in 15 patients, most frequently the affection was located in the diagonal branch of the left coronary artery. Stenosis of the left coronary artery trunk was diagnosed in one case. The correlation analysis revealed a strongly significant positive correlation between content of anti-OLDL and the degree of CS.
Conclusion. The level of anti-OLDL in CHD patients directly correlates with the degree of CS and is a marker of coronary atherosclerosis severity.

About the authors

Soreyya Asafovna Urazgil'deeva

Email: s_urazgildeeva@hotmail.com

Aleksandr Yur'evich Titkov

Email: alextitkov76@mail.ru

Lyubov' Vasil'evna Vasina

Email: lubov.vasina@gmail.com

Viktoriya Vital'evna Tsaregorodtseva

Email: vika.ru@rambler.ru

Viktor Savel'evich Gurevich

Email: ater@med122.com

S A Urazgildeeva

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

A Yu Titkov

L.G. Sokolov city hospital № 122, St-Petersburg

L.G. Sokolov city hospital № 122, St-Petersburg

L V Vasina

L.G. Sokolov city hospital № 122, St-Petersburg

L.G. Sokolov city hospital № 122, St-Petersburg

V V Tsaregorodtseva

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

V S Gurevich

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg

References

  1. Климов А. Н. Аутоиммунная теория атерогенеза и концепция модифицированных липопротеидов. Вестн. АМН СССР 1990; 11: 30-36.
  2. Sherer Y., Pauletto P., Shoenfeld Y. Atherosclerosis and Autoimmunity. Handbook of Systemic Autoimmune Disease.In: Doria A., Pauletto P. eds. The heart in systemic autoimmune diseases. Amsterdam. 2004. 89-95.
  3. Fitzgibbon G. M., Burggraf G. W., Groves T. D., Parker J. O. A double Master's two-step test: clinical, angiographic and hemodynamic correlation. Ann. Intern. Med. 1971; 74 (4): 509- 517.
  4. Friedwald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in lasma without use of the preparative uitracentrifuge. Clin. Chem. 1972; 18 (6): 499-502.
  5. Насонов Е. Л., Алекберова З. С., Калашникова Л. А. и др. Антифосфолипидный синдром (синдром Hughes); 10 лет изучения в России. Клин. мед. 1998; 2: 4-11.
  6. Sherer Y., Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies and atherosclerosis. Curr. Atheroscler.Rep. 2001; 3 (4): 328-333.
  7. Hamsten A., Norberg R., Bjorkholm M. et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1 (8473): 113-116.
  8. Насонов Е. Л., Карпов Ю. А., Алекберова З. С. и др. Антифосфолипидный синдром: кардиологические аспекты. Тер. арх. 1993; 11: 80-86.
  9. Holvoet P., Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J. 1994; 8 (15): 1279-1284.
  10. Vaarala O. Antibodies to oxidized LDL. Lupus 2000; 9 (3): 202-205.
  11. Гуревич В. С., Уразгильдеева С. А., Шатилина Л. В. и др. Изменение уровней антител к окисленным липопротеидам при применении аторвастатина у женщин с ишемической болезнью сердца в постменопаузе. Кардиология 2004; 4: 76-77.
  12. Maggy E., Perani G., Falaschi F. et al. Autoantibodies against oxidized low density lipoproteins in patients with coronary disease. Presse Med. 1994; 23 (25): 1158-1162.
  13. Erkkila F. T., Narvanen O., Lehto S. et al. Autoantibodies against oxidized low density lipoproteins and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vase. Biol. 2000; 20 (1): 204-209
  14. Lehtimaki T., Lehtinen S., Solakivi T. et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vase. Biol. 1999; 19 (1): 23-27.
  15. Puuronen M., Manttari M., Manninen V. et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 1994; 154 (22): 2605-2609.
  16. Wu R., Nityanand S., Berglund L. et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vase. Biol. 1997; 17 (11): 3159-3163.
  17. George J., Harats D., Bakshi E. et al. Anti-oxidized ow density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol.Lett. 1999; 68 (2-3): 263-266.
  18. Morton K. E., Gavaghan T. P., Krilis S. A. et al. Coronary artery bypass graft failure - an autoimmune phenomenon? Lancet 1986; 2 (8520): 1353-1357.
  19. Nilsson J., Regnstrom J., Frostegard J., Stiko A. Lipid oxidation and atherosclerosis. Herz 1992; 17 (5): 263-269.

Statistics

Views

Abstract - 57

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies